TSPO and hepatocellular carcinoma: Phosphoglycerate mutase 1 (PGAM1) inhibition and the mitochondrial translocator protein (TSPO) inhibitor PK11195 exert antitumour effects by promoting ferroptosis, and these compounds can synergize with anti-PD-1 immunotherapy in HCC 83,141.